BioStock: Respiratorius has taken several steps this autumn

Lund-based drug developer Respiratorius has reported several important milestones during the autumn. Among other things, its cash position was strengthened at the beginning of the third quarter, and positive preclinical results was reported in the RESP9000 project. BioStock contacted the company’s CEO Johan Drott for a comment on the third quarter and what milestones he is looking forward to.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/11/respiratorius-has-taken-several-steps-this-autumn/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se